Two new spirostanol saponins, (25S)-spirostane-1β,3β,5β-triol 3-O-β-D-glucopyrano- side 1 and rhodeasapogenin 3-O-β-D-glucopyranosyl-(1 → 4)-β-D-glucopyranoside 2, together with a known saponin, rhodeasapogenin...Two new spirostanol saponins, (25S)-spirostane-1β,3β,5β-triol 3-O-β-D-glucopyrano- side 1 and rhodeasapogenin 3-O-β-D-glucopyranosyl-(1 → 4)-β-D-glucopyranoside 2, together with a known saponin, rhodeasapogenin 3-O-β-D-glucopyranoside 3, were isolated from the underground parts of Tupistra chinensis Bak.. Their structures were determined by spectroscopic analysis.展开更多
Purpose: To clarify the impact of bone metabolism disorder on lumbago in Parkinson’s Disease (PD). Methods: Data was retrospectively analyzed from 52 patients with PD in our outpatient clinic for more than 1 year (me...Purpose: To clarify the impact of bone metabolism disorder on lumbago in Parkinson’s Disease (PD). Methods: Data was retrospectively analyzed from 52 patients with PD in our outpatient clinic for more than 1 year (mean age, 63 ± 4 years old;mean duration from onset, 6.3 ± 0.8 years). Patients’ characteristics, comorbid musculoskeletal disorders, serum bone metabolism biomarkers, and bone mineral density were examined. Results: Twenty-one PD patients (40.2%) had chronic lumbago. Severe comptocormia and scoliosis were the most common musculosketal disorders in this group (47.6%) affected by lumbago, followed by osteoporosis (14.3%), compression fracture (4.8%). There was no significant difference in the duration of PD, body mass index, frequency of falls, bone mineral density, tartrate-resistant acid phosphatase-5b, osteocalcin, and N-terminal telopeptide between PD patients with or without chronic lumbago. Multivaritae logistic regression analysis identified the independent predictors of chroni lumbago in PD patients as Hoen-Yahr stage (odds ration [OR] = 2.794, 95%CI 1.103 - 7.076), and elevated serum 1,25-OH<sub>2</sub> vitamin D level ([OR] = 0.92, 95%CI 0.86 - 98). Conclusion: Bone metabolism disorders are found to be associated with chronic lumbago in PD patients.展开更多
文摘Two new spirostanol saponins, (25S)-spirostane-1β,3β,5β-triol 3-O-β-D-glucopyrano- side 1 and rhodeasapogenin 3-O-β-D-glucopyranosyl-(1 → 4)-β-D-glucopyranoside 2, together with a known saponin, rhodeasapogenin 3-O-β-D-glucopyranoside 3, were isolated from the underground parts of Tupistra chinensis Bak.. Their structures were determined by spectroscopic analysis.
文摘Purpose: To clarify the impact of bone metabolism disorder on lumbago in Parkinson’s Disease (PD). Methods: Data was retrospectively analyzed from 52 patients with PD in our outpatient clinic for more than 1 year (mean age, 63 ± 4 years old;mean duration from onset, 6.3 ± 0.8 years). Patients’ characteristics, comorbid musculoskeletal disorders, serum bone metabolism biomarkers, and bone mineral density were examined. Results: Twenty-one PD patients (40.2%) had chronic lumbago. Severe comptocormia and scoliosis were the most common musculosketal disorders in this group (47.6%) affected by lumbago, followed by osteoporosis (14.3%), compression fracture (4.8%). There was no significant difference in the duration of PD, body mass index, frequency of falls, bone mineral density, tartrate-resistant acid phosphatase-5b, osteocalcin, and N-terminal telopeptide between PD patients with or without chronic lumbago. Multivaritae logistic regression analysis identified the independent predictors of chroni lumbago in PD patients as Hoen-Yahr stage (odds ration [OR] = 2.794, 95%CI 1.103 - 7.076), and elevated serum 1,25-OH<sub>2</sub> vitamin D level ([OR] = 0.92, 95%CI 0.86 - 98). Conclusion: Bone metabolism disorders are found to be associated with chronic lumbago in PD patients.
